GAGrigory V. Afonin

Grigory V. Afonin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Grigory V. Afonin has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Synchronous gastrointestinal stromal tumor and locally advanced gastric adenocarcinoma achieving complete pathomorphological response after neoadjuvant therapy

    by S.M. Volobuev, V.YU. Skoropad, V.N. Grinevich, E.I. Smolenov, G.V. Aphonin, S.A. Ivanov, A.D. Kaprin

    Two rare clinical cases of synchronous gastric gastrointestinal stromal tumor (GIST) and locally advanced adenocarcinoma are presented. In both cases, complete pathological regression of gastric adenocarcinoma was achieved following different neoadjuvant therapy regimens. In the first case (74-year-old female patient D.), neoadjuvant chemotherapy with the FLOT regimen was administered for cT3N0M0 gastric cancer (stage IIB), followed by D2 gastrectomy. Complete pathological response was confirmed (ypT0N0, Becker grade 1a). Morphological examination incidentally revealed a subserosal GIST measuring 0.5 cm in diameter with absent mitotic activity and a progression risk of 0% (Miettinen 2006). In the second case (76-year-old male patient G.), within a clinical trial, neoadjuvant chemoradiotherapy (total dose 46 Gy with capecitabine and oxaliplatin) was delivered for cT3N1M0 gastric cancer (stage III), followed by D2 gastrectomy. Pathological examination demonstrated complete tumor regression (ypT0N0, Becker grade 1a) and identified a 1 cm GIST with a progression risk of 0%. The patient declined adjuvant chemotherapy and remains disease-free after 67 months of follow-up. These observations illustrate a rare combination of two tumors of distinct histogenesis in which complete pathological response of gastric adenocarcinoma to neoadjuvant treatment was achieved.

  • Open Access

    Investigation of blood parameters related to the formation of neutrophil extracellular traps in patients with locally advanced non-small cell lung cancer

    by Anastasia E. Glukhareva, Глухарева Анастасия Евгеньевна, Lyudmila Yu. Grivtsova, Гривцова Л. Ю., Grigory V. Afonin, Афонин Г. В., Sergey A. Ivanov, Иванов С. А., Andrey D. Kaprin, Каприн А. Д.

    Background. Lung cancer remains the leading cause of mortality among all malignancies. Non-small cell lung cancer (NSCLC) accounts for approximately 80 % of all lung cancer cases, and 40 % of patients are diagnosed at an advanced, unresectable stage. The high prevalence and mortality associated with this disease necessitates the search for new therapeutic targets. Among the potential markers of metastasis and tumor progression is the biological phenomenon of neutrophil extracellular trap formation (NETosis). Several blood parameters associated with NETosis have been described, including double-stranded DNA, citrullinated histones, and myeloperoxidase-DNA complexes. Aim. To evaluate the presence and concentrations of double-stranded DNA, citrullinated histones and myeloperoxidase-DNA complexes in blood serum associated with the NETosis phenomenon in patients with locally advanced unresectable non-small cell lung cancer. Materials and methods. Serum samples from 49 primary patients with locally advanced unresectable NSCLC were examined at diagnosis. Citrullinated histone H3, myeloperoxidase-DNA complexes and double-stranded DNA (dsDNA) were measured by enzyme-linked immunosorbent assay. Citrullinated histone H3 was measured with a Cayman Chemical kit, myeloperoxidase-DNA complexes complexes on Nunc Polysorb plates sensitized with myeloperoxidase antibodies, and dsDNA with the Quant-iT PicoGreen dsDNA Assay Kit (Thermo Fisher Scientific, USA). Data were processed with Statistica v.13.3. Results. The frequency of observations (the number of patients) with values above the upper limit reported for donors was 100 % for dsDNA; citrullinated histone H3 exceeded the donor median in 26.5 % of cases (13 of 49). The median dsDNA concentration in patients was significantly higher than in healthy donors: 417.5 (347.2; 638.2) ng / ml, with individual values ranging from 267.9 to 1523.0 ng / ml. The analysis of myeloperoxidase-DNA complexes in patients was difficult due to the lack of a calibration curve for donors. Conclusion. Assessment of two independent parameters indicates a high probability of neutrophil extracellular traps in the blood of primary patients with unresectable NSCLC.

  • Results of the ESOSTAT multiple-center prospective study: analysis of 90-day postoperative morbidity and mortality after radical surgery for esophageal and esophagogastric junction cancer

    by A.B. Ryabov, N.M. Abdulkhakimov, V.G. Agadzhanov, M.V. Agasiev, A.E. Anisimov, G.V. Afonin, A.F. Bikmetov, F.P. Vetshev, S.V. Gamayunov, D.V. Erygin, et al.

    Objective. To evaluate 90-day morbidity and mortality rates after elective radical surgery for esophageal and esophagogastric junction cancer within the prospective multiple-center study ESOSTAT. Material and methods. The study included 230 patients from 18 oncology hospitals in the Russian Federation and the Republic of Belarus who underwent elective radical esophagectomy for primary esophageal cancer or esophagogastric junction cancer (Siewert I–II) between March 18 and September 18, 2024. Complications were uniformly recorded using the ESODATA system with severity graded according to the Clavien-Dindo classification. Univariate and multivariate logistic regression analyses were performed to identify risk factors of postoperative complications and mortality. Results. The 90-day mortality rate was 8.7%, in-hospital mortality — 4.8%. The overall complication rate was 41.3%, including surgical complications in 26.5% of patients and redo surgeries in 17.4% of cases. The most common complications were pulmonary (22.1%) and anastomotic leakage (11.3%). The mortality rate associated with anastomotic leakage was 19.2%. Multivariate analysis identified female sex (OR=0.732; 95% CI 0.548–0.978; p=0.035), ECOG status 2 (OR=10.142; 95% CI 1.575–65.366; p=0.015), surgery time (OR=1.003; 95% CI 1.001–1.005; p=0.006), and intraoperative blood loss (OR=1.001; 95% CI 1.000–1.002; p=0.027) as independent predictors of complications. Factors independently associated with 90-day mortality were Charlson comorbidity index >4 (OR=1.260; 95% CI 1.062–1.495; p=0.008), complicated course of esophageal cancer (OR=1.560; 95% CI 0.637–2.305; p=0.025), concomitant pulmonary diseases (OR=3.328; 95% CI 1.083–10.227; p=0.036), and any postoperative complication (OR=36.554; 95% CI 15.800–84.521; p<0.001). Conclusion. The ESOSTAT study is the first in Russia and Belarus to evaluate 90-day morbidity and mortality rates after esophagectomy. Our findings are comparable with international registries, support 90-day follow-up period and identify key prognostic factors. Risk factor analysis will allow patient stratification according to the likelihood of adverse outcomes, facilitate more rigorous patient selection, and ultimately improve safety of surgical treatment.

  • Open Access

    Treatment of HER2/neu-positive breast cancer with brain metastases: a clinical case

    by G. V. Afonin, A. E. Glukhareva, E. I. Kupriyanova, A. A. Sofiychuk, А. S. Belokhvostova, N. A. Falaleeva, S. A. Ivanov, A. D. Kaprin

    Breast cancer (BC) remains one of the most common oncological diseases among women worldwide, ranking among the leading causes of both cancer incidence and mortality. The main cause of unfavorable outcomes in BC is distant metastasis. The brain is one of the most frequent sites of distant metastatic spread, which significantly complicates treatment and worsens prognosis. This is the blood–brain barrier, which limits the penetration of many chemotherapeutic agents, as well as the aggressive biology of the tumor.This article presents a clinical case of effective use of modern targeted agents in a patient with diagnosed breast cancer who initially had an unfavorable prognosis and disease progression after previous therapy. Particular attention is paid to treatment strategy selection and the use of contemporary targeted therapies that demonstrated clinical efficacy.The described case illustrates the potential of a personalized approach in the treatment of this category of patients, including the possibility of disease control and improvement of clinical outcomes. The analysis of the presented clinical case indicates the need for further development of systemic maintenance therapy, as well as broader implementation of targeted and combined treatment approaches. Individualization of therapeutic strategies taking into account tumor biological characteristics and prior treatment history may contribute to improved treatment efficacy and quality of life.

  • Predicting 90-day postoperative mortality after esophagectomy using machine learning technology: a comparative evaluation of the model with foreign analogues

    by K.I. Salimzyanov, A.B. Ryabov, V.M. Khomyakov, I.V. Kolobaev, E.I. Smolenov, N.M. Abdulkhakimov, G.S. Pogosyan, G.V. Afonin

    Objective. To compare the performance of a machine-learning-based model for predicting 90-day postoperative mortality after esophagectomy (EsoRisk) with existing prognostic scales, the ACS NSQIP and Esodata (IESG), in a single independent patient sample. Material and methods. A retrospective cohort study was conducted, including 100 patients with resectable esophageal and cardioesophageal junction cancer (Siewert I) who underwent esophagectomy at the P.Herzen Moscow Oncology Research Institute and the A.Tsyb Medical Radiological Research Center from January 2024 to November 2025. During the 90-day postoperative period, in-hospital, 30-, and 90-day mortality, as well as the incidence of postoperative complications, were assessed. The ACS NSQIP, Esodata (IESG), and EsoRisk scores were used for direct comparative analysis. Model validity was assessed using the AUC-ROC, AUPRC, Accuracy, and Brier score metrics. Results. Postoperative complications were registered in 42% of patients, Clavien–Dindo complications ≥ IIIA — in 29%. In-hospital mortality was 8%, 30-day — 2%, 90-day — 8%. In terms of discriminatory ability, EsoRisk was superior to the compared scales: AUC-ROC was 0.87 versus 0.78 for Esodata (IESG) and 0.55 for ACS NSQIP; AUPRC — 0.81 versus 0.36 and 0.36, respectively; Accuracy — 0.70 versus 0.54 and 0.46; the Brier score was minimal in the EsoRisk model and amounted to 0.10. Conclusion. The EsoRisk model, based on machine learning methods, demonstrated higher accuracy in predicting 90-day postoperative mortality after esophagectomy compared to the ACS NSQIP and Esodata (IESG) scores. These data confirm the potential of using machine learning algorithms for preoperative risk stratification in patients with esophageal cancer. The presented model can be recommended for use in institutions specializing in the surgical treatment of esophageal cancer.

  • Open Access

    Clinical observation of rib resection using a patient-specific 3D implant in the surgical treatment of chondrosarcoma

    by G. V. Afonin, D. Yu. Mironova, E. I. Smolenov, Z. M. Salimov, A. A. Kurilchik, М. С. Бондарь, S. A. Ivanov, A. D. Kaprin

    To date, surgical treatment remains the main therapeutic option for patients with chest wall tumors. Given the importance of preserving the structural integrity of the thoracic cage during extensive resections, the choice of reconstruction method for post-resection chest wall defects remains one of the key challenges in thoracic surgery.This clinical case report presents the treatment outcomes of a 64‑year-old female patient diagnosed with primary multiple metachronous malignancies who underwent rib resection followed by alloplastic reconstruction using a patient-specific 3D implant made of a nickel–titanium alloy. The implant was designed based on an individualized model and featured a double-locking mechanism using clamp-type fixation. At the 12‑month follow-up, no evidence of tumor recurrence was detected; the implant remained stable, the physiological volume of the thoracic cavity was preserved, and no signs of paradoxical respiration were observed. The proposed patient-specific modular 3D implant is convenient for intraoperative placement, allowing minimization of the risk of bleeding and infectious complications, as well as reduction of operative time. The technique of sternal and rib reconstruction using a patient-specific modular 3D implant is safe and effective and can be widely implemented in clinical practice.

  • Diagnostic capabilities of multipoint transthoracic biopsy under ultrasound navigation of mediastinal formations

    by A.S. Yakusheva, P.D. Bespalov, S.A. Ivanov, I.V. Kolobaev, Z.M. Salimov, G.V. Afonin

    Mediastinal tumors cover a wide range of malignant neoplasms arising in the chest cavity. Due to the many structures and organs located in this area, mediastinal cancer has different histological forms. Thus, both primary benign and malignant tumors, as well as tumors of secondary genesis, can arise. In recent years, there has been an increase in the incidence of mediastinal cancer. Morphological verification is crucial for determining patient treatment tactics and prognosis of the disease. Objective. To evaluate the effectiveness of multicore transthoracic biopsy (TTB) under ultrasound navigation in the diagnosis of mediastinal tumors. Material and methods. Based on the A. Tsyb Medical Radiological Research Centre 138 patients with mediastinal tumors underwent multipoint TTB under ultrasound navigation. The age of the patients ranged from 19 to 74 years. There were 92 men (67%), 46 (33%) women. The size of the mediastinal tumor along the short axis ranged from 15 mm to 110 mm. Depending on the size and structure of the tumor, the number of puncture points varied from 3 to 10. Results. As a result of the study, all patients included in the study underwent multipoint TTB under ultrasound navigation of mediastinal tumors. In all cases, material suitable for histological examination was obtained. During the study, Hodgkin’s lymphoma was morphologically verified in 42% of patients, mediastinal large B-cell lymphoma — 30%, thymoma — 14%, T-cell lymphoblastic lymphoma — 6%, monophasic synovial sarcoma — 2%, germ cell tumor — 6%. Conclusion. Due to its high information content and sensitivity, the absence of radiological burden on the patient and staff, as well as the safety and efficiency of the procedure, this technique represents a promising alternative to traditional CT-controlled puncture of tumors of the upper and anterior mediastinum.

  • Open Access

    Study of circulating regulatory T cells in solid cancers

    by T. Yu. Mushkarina, Е. Г. Кузьмина, V. A. Biryukov, G. V. Afonin, L. Yu. Grivtsova, Л. Ю. Гривцова

    Regulatory T cells (Tregs) play a key role in maintaining peripheral immune tolerance. Disorders in their functioning are associated with the development of autoimmune, allergic and oncological diseases. The aim of the study was to evaluate the involvement of circulating Treg cells in the development of solid malignancies. Materials and methods. The level of Treg cells (CD 45 + CD 4 + CD 25 + CD 127 -/low ) in the peripheral blood of patients with cervical cancer (CC, n=10), prostate cancer (PC, n=23) and lung cancer (LC, n=10) was determined by flow cytofluorometry. The control group consisted of 40 healthy donors. The Mann-Whitney U-test was used to compare the indicators of the groups. Results . The study showed an increased level of circulating Treg cells in patients with CC, PC and LC compared with the control group (pConclusion . The data obtained confirm the universal role of Treg cells in the development and progression of solid tumors, which indicates the promise of immunomodulatory approaches aimed at regulating the activity of these cells.

  • Short-term outcomes of the McKeown esophagectomy for thoracic esophageal cancer: a multiple-center study

    by A.B. Ryabov, O.V. Pikin, V.M. Khomyakov, I.V. Kolobaev, E.A. Toneev, N.M. Abdulkhakimov, S.V. Gamayunov, N.M. Kiselev, O.A. Alexandrov, D.D. Sobolev, et al.

    Objective. To analyze short-term outcomes of the McKeown esophagectomy in 4 cancer centers of the Russian Federation. Material and methods. The study included 175 patients who underwent open, hybrid or minimally invasive McKeown esophagectomy between 2016 and 2023 in 4 cancer centers of the Russian Federation. Traditional open esophagectomy was performed in 69 (39.4%) patients, hybrid — in 78 (44.6%), minimally invasive — in 28 (16%) patients. Results. Median time of minimally invasive surgery was 395 min [358.25; 436.25], hybrid procedure — 357.5 min [300.00; 403.75], open esophagectomy — 315 min [265.00; 390.00] (p<0.001). Mean blood loss was 175, 150 and 300 ml, respectively (p<0.001). Conversion rate for hybrid interventions was 2.5%, for minimally invasive esophagectomy — 3.5%. Mean number of resected lymph nodes was higher in minimally invasive groups (open — 19.7±7.5; hybrid — 21.3±13.1; minimally invasive esophagectomy — 21.7±12.4 p=0.007). Major postoperative complications (TMM classification) comprised 8.7% in open surgeries and 20.7% in hybrid and minimally invasive procedures (p=0.031). Pulmonary complications were more common after open esophagectomy (17.4%) compared to hybrid and minimally invasive procedures (7.5%) (p=0.041). Incidence of type 2 and 3 anastomotic leaks was 6.4% in hybrid surgery, 8.6% in open surgery and 10.7%in minimally invasive procedures (p=0.387). Postoperative in-hospital mortality was 8.6% for open esophagectomy, 5.1% for hybrid esophagectomy and 3.5% for minimally invasive procedures (p=0.049). Hospital-stay was 19 days for open esophagectomy and 14 days for hybrid and minimally invasive procedures (p=0.219). Conclusion. Minimally invasive esophagectomy for thoracic esophageal cancer significantly reduces the incidence of postoperative pulmonary complications and intraoperative blood loss, as well as increases the number of removed lymph nodes.


  • Open Access

    Accompanying immunotherapy and quality of life in patients with locally advanced non-small cell lung cancer who received simultaneous chemoradiotherapy

    by А. Е. Glukhareva, G. V. Afonin, L. Yu. Grivtsova, S. A. Ivanov, A. D. Kaprin, Л. Ю. Гривцова

    Background. Lung cancer continues to be in the leading positions in mortality among all malignant neoplasms; 85 % of all cases are nonsmall cell lung cancer (NSCLC), and in 40 % of patients the process is diagnosed at a common unresectable stage. Chemoradiotherapy is the standard of treatment for this category of patients, which allows to improve the results of local control and overall survival. In Russia, chemoradiotherapy accounts for about 4 % of all treatment methods. Perhaps this is due to high toxicity of this method and, as a result, a deterioration in quality of life of patients.Aim. To assess the quality of life of patients with locally advanced NSCLC during simultaneous chemoradiotherapy in combination with and without accompanying immunotherapy.Materials and methods. The study included 60 patients with locally advanced NSCLC. The study group (n = 30) received a radical course of simultaneous chemoradiotherapy with the use of accompanying immunotherapy with azoximer bromide. Patients in the control group (n = 30) underwent a course of simultaneous chemoradiotherapy in the standard mode. We evaluated the criteria of quality of life in patients using questionnaires EORTC QLQ-LC13, EQ-5D-5L, EORTC QLQ-C30.Results. In the study group, an improvement in most of the parameters of quality of life and a decrease in the severity of symptoms were demonstrated compared with the control group.Conclusion. The study demonstrated a tendency to reduce hematological toxicity and improve the quality of life of patients with NSCLC. This allows us to consider the possibility of using accompanying immunotherapy in combination with chemoradiotherapy as an additional therapeutic option that improves the quality of life of patients and the tolerability of the treatment.